Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp. reports developments tied to its hormone optimization and healthy aging business, which supports Biote-certified medical providers through training, practice development, operational services and personalized hormone therapy programs. Company updates commonly cover procedure revenue, dietary supplement sales, new provider and clinic growth, commercial team expansion and technology or sales investments aimed at the practitioner network.
Biote news also includes quarterly financial results, outlook commentary, share repurchases, organizational changes and product-supply matters. Its operating updates distinguish procedure-based revenue from Biote-branded dietary supplements and have included disclosures related to Asteria Health, the company’s wholly owned 503B manufacturing subsidiary.
Biote (NASDAQ: BTMD) reported second quarter 2026 revenue of $44.2 million, down 9.5% year over year, with procedure revenue falling 13.9% to $30.3 million and dietary supplements revenue rising 5.7% to $11.4 million. Gross margin declined to 65.4% from 71.6%, reflecting higher costs and lower efficiencies following a voluntary recall of certain hormone pellets shipped by Asteria Health.
Biote posted an operating loss of $3.5 million versus income of $10.8 million a year ago, and a net loss of $7.4 million (diluted loss per share of $0.23) versus net income of $3.9 million ($0.10 per diluted share). Adjusted EBITDA decreased to $5.6 million from $15.2 million, with margin dropping to 12.6% from 31.1%. As of June 30, 2026, cash and cash equivalents were $11.2 million and total liabilities were $159.9 million, resulting in total stockholders’ deficit of $58.2 million. For full-year 2026, Biote now expects revenue above $175 million and Adjusted EBITDA above $25 million, with procedure revenue improving sequentially in the third and fourth quarters but remaining negative year over year.
Biote (Nasdaq: BTMD) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market close. The company will host a conference call the same day at 5:00 p.m. ET, accessible by phone and live webcast, with a replay available on its Investor Relations Events page.
Biote (NASDAQ: BTMD) appointed Komal Bajaj, MD, MS as Chief Medical Officer, effective June 1, 2026. She is a board-certified OB/GYN and reproductive geneticist with over 20 years of experience in clinical practice, quality, academic medicine, innovation, and systems leadership.
Dr. Bajaj previously served as Chief Quality Officer at Jacobi Hospital and North Central Bronx Hospital within NYC Health + Hospitals, leading quality and safety programs for a system serving about one million patients. She has led initiatives in AI governance, simulation-based training, diagnostic excellence, patient safety, prenatal molecular diagnostics, and digital health solutions.
Biote (NASDAQ: BTMD) appointed Bob Peterson, current Chief Financial and Chief Business Officer, as Interim CEO and Director effective June 8, 2026. CEO Bret Christensen will step down for family and personal reasons but remain on the Board, while Chairman Marc Beer becomes Executive Chairman.
Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and expects a return to procedure revenue growth in the second half of 2026.
Biote (NASDAQ: BTMD) reported Q1 2026 results: revenue $44.9M (down 8.3% YoY), procedure revenue $31.3M (down 13.2%), and dietary supplements $11.0M (up 19.1%). Gross margin declined to 68.9% from 74.3%. Net income was $2.7M and diluted EPS $0.06. Adjusted EBITDA was $8.7M and margin 19.4%. The company cited a voluntary pellet product recall and supply constraints, expects procedure revenue to resume growth in H2 2026, and reaffirmed 2026 guidance of revenue above $190M and Adjusted EBITDA above $38M.
biote (Nasdaq: BTMD) will release first quarter 2026 financial results on Wednesday, May 6, 2026 after market close and will host a conference call the same day at 5:00 p.m. ET.
Investors may dial U.S. and international numbers or join a live webcast; a replay will be posted on the company’s Investor Relations Events page shortly after the call.
Biote (NASDAQ: BTMD) reported Q4 2025 revenue of $46.4M and full-year 2025 revenue of $192.2M. Q4 procedure revenue fell 13.0% while dietary supplements grew 16.0%. 2025 net income was $31.6M with diluted EPS of $0.74. 2026 guidance: revenue above $190M and Adjusted EBITDA above $38M, with an expected H1 2026 procedure revenue decline and return to growth in H2 2026.
biote Corp. (Nasdaq: BTMD) will release fourth quarter and full year 2025 financial results on Wednesday, March 11, 2026 after market close.
A conference call to discuss results is scheduled the same day at 5:00 p.m. ET. According to the company, the call can be accessed by dialing the provided U.S. and international numbers or via a live webcast; a replay will be posted on the investor events page.
Biote (NASDAQ: BTMD) reported third quarter 2025 results with revenue of $48.0M (down 6.7% YoY), gross margin 71.8%, net income of $9.2M and diluted EPS of $0.22. Procedure revenue fell 10.4% while dietary supplements grew 8.4%. Adjusted EBITDA was $12.9M with a 26.9% margin. The company repurchased ~1 million Class A shares and completed share repurchase payments to settle legacy earnout obligations totaling $12.5M and an agreed $18.5M payment due Jan 2026. Biote reiterated 2025 guidance: revenue above $190M and Adjusted EBITDA above $50M.
biote (Nasdaq: BTMD) will release Q3 2025 financial results on Wednesday, November 5, 2025 after market close. A conference call to discuss results is scheduled the same day at 5:00 p.m. ET.
Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (international) or via the live webcast. A replay of the webcast will be posted on the Events page of the biote investor relations website shortly after the event concludes.